ArticleNeurochemical research2014
Melatonin acts as antioxidant and improves sleep in MS patients.
Article in Neurochemical research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Melatonin supplementation in multiple sclerosis: a systematic review of clinical, imaging, biomarker, and safety outcomes.Frontiers in neurology · 2026Pooled it
- Clinical efficacy and safety of melatonin supplementation in multiple sclerosis: a systematic review.Inflammopharmacology · 2023Pooled it
- The effectiveness of a motivational text-messaging program for smoking cessation after coronary angioplasty: a quasi-experimental study.BMC research notes · 2023Trial
- Results of a randomized, double blind, placebo controlled, crossover trial of melatonin for treatment of Nocturia in adults with multiple sclerosis (MeNiMS).BMC neurology · 2018Trial
- Melatonin Pharmacological Blood Levels Increase Total Antioxidant Capacity in Critically Ill Patients.International journal of molecular sciences · 2017Trial
- Role of Caveolin-1 in Inflammation: Genetic Predisposition and Potential Implication for Multiple Sclerosis.Genes · 2026Review
- Effects of exogenous melatonin on photosynthesis physiology biochemistry of blue honeysuckle seedlings under saline-alkali stress.BMC plant biology · 2026Article
- Circadian Clock: A Regulator of Immunity in Autoimmune Diseases.Immunity, inflammation and disease · 2025Review
- Melatonin inhibits salivary gland epithelial cell ferroptosis via the NRF2/HO-1/GPX4 signaling pathway in primary Sjögren's syndrome.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- The Effects of Antioxidant Approved Drugs and Under Investigation Compounds with Potential of Improving Sleep Disorders and their Associated Comorbidities Associated with Oxidative Stress and Inflammation.Mini reviews in medicinal chemistry · 2025Review
- Antioxidant Therapies in the Treatment of Multiple Sclerosis.Biomolecules · 2024Review
- Significance of Melatonin in the Regulation of Circadian Rhythms and Disease Management.Molecular neurobiology · 2024Review
- Sleep counts! Role and impact of sleep in the multimodal management of multiple sclerosis.Journal of neurology · 2023Review
- Influence of hormones in multiple sclerosis: focus on the most important hormones.Metabolic brain disease · 2023Review
- Pharmacokinetics and Pharmacodynamics of Key Components of a StandardizedAntioxidants (Basel, Switzerland) · 2022Article
- Use of Benzodiazepines and Z-Drugs in Multiple Sclerosis.Frontiers in neurology · 2022Article
- Decreased Cerebrospinal Fluid Antioxidative Capacity Is Related to Disease Severity and Progression in Early Multiple Sclerosis.Biomolecules · 2021Article
- Graphene-Based Sensors for the Detection of Bioactive Compounds: A Review.International journal of molecular sciences · 2021Review
- Insomnia in neurological diseases.Neurological research and practice · 2021Article
- Oxidative/Nitroxidative Stress and Multiple Sclerosis.Journal of molecular neuroscience : MN · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The relationship between the prevalence of multiple sclerosis (MS) and sunlight's ultraviolet radiation was proved. Oxidative stress plays a role in the pathogenic traits of MS. Melatonin possesses antioxidative properties and regulates circadian rhythms. Sleep disturbances in MS patients are common and contribute to daytime fatigue. The aim of study was to evaluate 5 mg daily melatonin supplementation over 90 days on serum total oxidant status (TOS), total antioxidant capacity (TAC) and its influence on sleep quality and depression level of MS patients. A case-control prospective study was performed on 102 MS patients and 20 controls matched for age and sex. The Kurtzke's Expanded Disability Status Scale, magnetic resonance imaging examinations, Athens Insomnia Scale (AIS), Beck Depression Inventory questionnaires were completed. Serum TOS and TAC levels were measured. We observed higher serum levels of TOS in all MS groups, while after melatonin treatment the TOS levels significantly decreased. The TAC level was significantly lower only in mitoxantrone-treated group and it increased after melatonin supplementation. A strong positive correlation between T1Gd(+) number lesions and TAC level in interferon-beta-1A group was observed. AIS group mean score above 6 defining insomnia were observed in interferon-beta-1B-group, glatiramer acetate-group and mitoxantrone-group: 6.62 ± 2.88, 8.45 ± 2.07, 11.1 ± 3.25, respectively. After melatonin treatment the AIS mean scores decrease in glatiramer acetate-group and mitoxantrone-group achieving 5.25 ± 1.14 and 7.08 ± 2.39, respectively (p < 0.05). Finding from our study suggest that melatonin can act as an antioxidant and improves reduced sleep quality in MS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.